Brian M. Wolpin

researcher, ORCiD ID=0000-0002-0455-1032

5 stories

12 quotes

That time was not built into my talk,
Based on the data we have now, I think this drug is relevant to all patients with pancreatic cancer, assuming that they have metastatic cancer,
It’s been incredibly hard to drug that mutation,
Pancreatic ductal adenocarcinoma is among the most challenging and lethal cancers, with limited therapeutic options,
  • recalled Brian Wolpin, lead investigator of the trial at Dana-Farber Cancer Institute in Boston, Massachusetts, on Sunday in Chicago
    Le Mondelemonde.fr/en/science…
These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer,
Pancreas cancer may be the first for this drug, but there will be others,
  • said Dr. Brian Wolpin, who also led research on daraxonrasib and directs the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute
    NBC Newsnbcnews.com/health/health…

Earlier